Clinical trials: Liver Disease Chronic
Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection
A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
The primary objectives of this study are to assess the safety of ABT-450/r/ABT-267 with and without ABT-333 coadministered with and without ribavirin (RBV) for 12 and 24 weeks in HCV GT1- or 4-infected participants with HIV-1…
- Conditions
- Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis and Non-cirrhotics
- Trial name
- TURQUOISE-I (NCT01939197)
- Testing
- ABT-450/r/ABT-267, ABT-333, ribavirin
- Volunteers
- 318 people
- Sponsor
- AbbVie
Non-alcoholic Fatty Liver Disease, Chronic Kidney Disease
Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease
The present study investigates relationship between non-alcoholic fatty liver disease and its risk factors, such as genetic background and diseases, such as chronic kidney disease and diabetes mellitus.
- Conditions
- Non-alcoholic Fatty Liver Disease, Chronic Kidney Disease, Diabetes Mellitus
- Trial name
- NAFLDDMCKD (NCT02947568)
- Testing
- non-interventional study
- Where
- Hungary
- Volunteers
- 600 people
- Sponsor
- University of Pecs
Hepatitis B, Chronic Hepatitis B
A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALN-HBV in healthy adult volunteers and patients with chronic hepatitis B virus (HBV) infection.
- Conditions
- Hepatitis B, Chronic Hepatitis B, Hepatitis B, Chronic, Hepatitis B Infection
- Trial name
- NCT02826018
- Testing
- ALN-HBV, Sterile Normal Saline (0.9% NaCl)
- Where
- 9 sites in Australia, Hong Kong and 4 more
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Chronic Liver Disease, NASH - Nonalcoholic Steatohepatitis
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects
A Phase 1a, Double Blind, Placebo-Controlled, Single-Center, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Volunteers
- Trial name
- NCT04146805
- Testing
- BLD-0409
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Blade Therapeutics
Hepatitis C, Chronic
Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism
The purpose of this study is to examine whether neurocognitive impairments experienced by patients with chronic hepatitis C virus (HCV) infection can be reversed by treating HCV, with a new combination of direct acting antiviral…
- Trial name
- HEPCOG-II (NCT02292966)
- Testing
- DCV/ASV/BCV
- Where
- 2 sites in Australia
- Sponsor
- Kirby Institute
Hepatitis C, Chronic
An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C
The investigators will assess whether patients with the Hepatitis C virus (HCV) who are prescribed direct-acting antiviral (DAA) medications experience higher rates of adverse events than patients with HCV who are untreated.
- Trial name
- NCT03423641
- Testing
- Direct Acting Antivirals
- Volunteers
- 33,808 people
- Sponsor
- Kaiser Permanente
Hepatitis C
Effect of Strategies for the Treatment of Chronic Hepatitis C in Colombia
Hepatitis C is a public health problem and the high cost of the Direct-Acting Antivirals (DAA) is one of the main limitations for treatment worldwide.
- Trial name
- HEPCSTRATEGY (NCT03895294)
- Testing
- Health care under the strategic purchase-Clinical pathway, Usual care process prior strategic purchase-clinical pathway
- Where
- Colombia
- Volunteers
- 124 people
- Sponsor
- Universidad de Antioquia
Chronic Hepatitis B
Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B
The "Chinese PAC" study (CLDT600ACN03) will evaluate the efficacy and safety of open label telbivudine in 2,200 compensated Chronic Hepatitis B (CHB) adults.
- Trial name
- Chinese PAC (NCT00781105)
- Testing
- Telbivudine
- Where
- China
- Volunteers
- 2,200 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C
High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV
Comparison of virological breakthrough/relapse rate after dose adjustments and sustained virological response rate will be assessed by the type of induction.
- Trial name
- NCT00381953
- Testing
- Peginterferon alfa-2a, Interferon alfa-2a, Ribavirin
- Where
- Netherlands
- Volunteers
- 33 people
- Sponsor
- Foundation for Liver Research
Chronic Hepatitis B
Long Term Follow-up of Pegylated-Interferon Alpha-2b
The aim of this study was to investigate the long term outcome of Peginterferon alpha-2b with or without the addition of lamivudine in patients with chronic hepatitis B
- Trial name
- NCT00146705
- Testing
- blood samples are taken once
- Where
- Netherlands
- Volunteers
- 266 people
- Sponsor
- Foundation for Liver Research
Safety Issues
Direct Acting Anti-Viral's In Chronic HCV Patients
The objective of the study is to determine the safety of DAA's among chronic HCV patients. The outcomes of the study are; To determine the frequency of adverse events while receiving DAAs with or without RBV and/or Pegylated…
- Trial name
- NCT04664894
- Testing
- Sofosbuvir
- Where
- Pakistan
- Volunteers
- 511 people
- Sponsor
- Getz Pharma
Alpha 1-Antitrypsin Deficiency
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency
The purpose of this clinical study is to assess the safety and tolerability of Alpha-1 MP in adult Alpha1-antitrypsin deficient patients.
- Trial name
- STAMP (NCT00301366)
- Testing
- alpha-1 proteinase inhibitor (human)
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 38 people
- Sponsor
- Grifols Therapeutics LLC
Chronic Hepatitis B
A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
Studies have shown that chronic hepatitis B patients with low levels of HBsAg after nucleos(t)ide analog therapy have a higher chance of functional cure with sequential or combined pegylated interferon therapy, with about 30-50%…
- Trial name
- NCT06707922
- Testing
- Peginterferon α-2b Injection; Tenofovir Alafenamide Fumarate
- Where
- 30 sites in China
- Volunteers
- 350 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Hepatitis C, Chronic
Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients
Chronic hepatitis C virus (HCV) infection is prevalent in the world, affecting 3% of the world's population. The current standard of therapy is pegylated interferon and ribavirin, reaching 54-63% of successful rates.
- Trial name
- NCT00495131
- Testing
- Pegylated interferon alfa-2a plus ribavirin
- Where
- 6 sites in Taiwan
- Volunteers
- 308 people
- Sponsor
- National Taiwan University Hospital
Chronic Liver Disease (CLD), Healthy Volunteers
Equivalence of New Breath AnalyzerCompared to Currently BreathID System in Assessment of Liver Function
The aim of the study is to confirm that the new generation state of the art breath analyzer gives equivalent results to the previous model of the Exalenz breath analyzer.
- Trial name
- NCT02187601
- Testing
- MPBA System, BreathID
- Where
- Israel
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Meridian Bioscience, Inc.
Chronic Hepatitis C
Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy
This study is being conducted to compare the safety, effectiveness and tolerance of valopicitabine (NM283) when used alone and when valopicitabine is used together with pegylated interferon in hepatitis C treatment failure…
- Trial name
- NCT00120861
- Testing
- valopicitabine, pegylated interferon, ribavirin
- Where
- 11 sites in United States
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B, HIV Infections
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral…
- Trial name
- NCT05551273
- Testing
- Selgantolimod
- Where
- 12 sites in United States, Brazil and 2 more
- Volunteers
- 29 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis B
Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
The primary objectives of this study are to evaluate the safety and tolerability of study treatment(s) (selgantolimod-containing combination therapies) and to evaluate the efficacy of study treatment(s) as measured by the…
- Trial name
- NCT04891770
- Testing
- Tenofovir Alafenamide, VIR-2218, Nivolumab
- Where
- 26 sites in Australia, Denmark and 6 more
- Volunteers
- 103 people
- Sponsor
- Gilead Sciences
Fatty Liver, Cirrhosis
Development of a Breath Test for Monitoring Patients With Liver Disease
The purpose of this study is to determine the safety and efficacy of the Oridion Breath ID machine in monitoring liver metabolic functions.
- Trial name
- NCT00244569
- Testing
- 13C-Methacetin, Breath ID Machine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Virginia Commonwealth University
Hepatitis B, Chronic
Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]
This is a Phase II Investigator-Initiated Study to understand the vaccinal effect of HBsAg monoclonal Ab VIR-3434 in chronic hepatitis B infection.
- Trial name
- NCT06216470
- Testing
- VIR-3434
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto